Bioidea Roundtable Presentation: December 2, 2019
The Bioidea team invites you to join healthcare investors for the private, invitation-only roundtable featuring Delcath Systems, Inc.
Location: Midtown Manhattan (address is private)
Date: Monday, December 2, 2019
Time: 5:30pm – 7:30pm
Complimentary appetizers, hors d’oeuvres, beer and wine throughout the evening
About Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company’s investigational products include melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its clinical development program consists of FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial that is in Phase 3 clinical trial for intrahepatic cholangiocarcinoma. It also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe.
Partner
Ingalls & Snyder is a registered investment advisor and broker-dealer based in New York City. We provide investment management and related services to private clients and institutional investors